The effectiveness of CP and hyperimmunoglobulin in patients diagnosed with COVID-19 is proposed to differ according to the time of transfusion, illness severity, volume administered, neutralizing antibody concentration, risk of antibody-dependent enhancement, and other adverse events [9]. This evidence concerns the gene CP and COVID-19.